NEW YORK (
) hit a new 52-week high Thursday as it traded at $26.52 compared with its previous 52-Week high of $26.51. Talecris is changing hands at $26.48 with 7,700 shares traded as of 9:37 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.
Talecris has a market cap of $3.3 billion and is part of the
industry. Shares are up 13% year to date as of the close of trading on Wednesday.
Talecris Biotherapeutics Holdings Corp., a biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. The company has a P/E ratio of 20.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 16.
- Practice your TLCR trading strategies and win cash in our stock game.
TheStreet Ratings rates Talecris as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the company has not been very careful in the management of its balance sheet. You can view the full
52-week high stocks
or get investment ideas from our